Adiponectin and its receptors in non-alcoholic steatohepatitis


Background: Adiponectin, an adipocyte derived polypeptide, has been shown to alleviate steatosis and inflammation in mice with non-alcoholic fatty liver disease.

Aim: In the present study, we wished to define liver expression of adiponectin and its receptors in morbidly obese patients undergoing bariatric surgery. Patients with non-alcoholic steatohepatitis (NASH) or simple steatosis were investigated to test whether dysregulation of this system might be involved in these disorders.

Patients and methods: Liver mRNA expression of adiponectin and its recently cloned receptors RI and RII (adipoRI and adipoRII) were analysed by fluorescence based real time polymerase chain reaction in 13 patients with NASH and nine with simple steatosis. Adiponectin and adipoRII protein expression were assessed by immunohistochemistry in a subgroup of patients.

Results: Adiponectin and adipoRII mRNA expression were significantly reduced in liver biopsies of patients with NASH compared with simple steatosis while no difference was found in adipoRI mRNA expression. In NASH, adipoRII mRNA expression was negatively correlated with serum aspartate aminotransferase levels, serum alanine aminotransferase levels, and grade of fibrosis. Liver adiponectin protein expression was mainly found in endothelial cells of portal vessels and liver sinusoids whereas adipoRII expression was seen in hepatocytes only. Adiponectin and adipoRII staining were lower in biopsies of subjects with NASH compared with simple steatosis.

Conclusion: Reduced hepatic expression of adiponectin and adipoRII might be of pathophysiological relevance in non-alcoholic fatty liver diseases.

N on-alcoholic steatohepatitis (NASH) is frequently associated with abdominal obesity, hypertension, and diabetes. Insulin resistance has been implicated as a key mechanism in the pathogenesis of NASH. Numerous substances, mainly released by adipocytes, are thought to contribute to peripheral insulin resistance. These include proinflammatory cytokines such as interleukin (IL)-6 and tumour necrosis factor α (TNF-α) as well as leptin, resistin, and also acrp30/adiponectin/adipoQ. Adiponectin is an antidiabetic and antiatherogenic acting polypeptide that is abundantly expressed in skeletal muscle, adipoRII is pre-
Laboratory measurements
Venous blood was drawn after an overnight fast and plasma or serum was obtained by centrifugation at 3000 rpm for 10 minutes at 4°C immediately after blood collection. Plasma and serum samples were either used immediately for analysis or were stored frozen at −80°C.

Insulin sensitivity was estimated by the homeostasis model assessment (HOMA) index. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (γ-GT), insulin, and glucose concentrations were measured using commercially available enzymatic kits. Serum adiponectin concentrations were determined using a commercially available radioimmunoassay kit (Linco Research Inc, St Charles, Missouri, USA).

RNA isolation
Liver biopsies were collected by Tru-cut from each subject. Total RNA was extracted from frozen liver by the acid guanidinium phenol chloroform method using Trizol reagent (Gibco, Gaithersburg, Maryland, USA). Extracted RNA was quantified by spectrophotometry. Reverse transcription of 1 μg of RNA was performed using the Omniscript RT Kit (Qiagen, Hilden, Germany).

Fluorescence based real time polymerase chain reaction
mRNA of adiponectin and adiponectin receptors were determined by fluorescence based real time polymerase chain reaction (PCR). Primers were designed with primer express software (Perkin-Elmer Applied Biosystems, Warrington, UK). Primers included: adipoRI: forward: 5’-ACT GAG AAG AGA AAA ACA AAA ATA AAT CAT AC-3’ and reverse: 5’-GAA TGC AGG GTG TGG GC-3’; adipoRII: forward: 5’-GCA GTA TGT CAT CTC GGA GGG-3’ and reverse: 5’-GCT ATC AGC ATC AAC CAG C-3’; adiponectin: forward: 5’-AGA TGG CAC CCC TGG TGA G-3’ and reverse: 5’-GGG TAC TCC GTG TCC TTC G-3’; TaqMan Probes: adipoRII: 5’-TCA AAG GAT GGA GTG CAT CAA TTG GGA G-3’; adiponectin: 5’-CTT AAG GCC GCC ACC ATA GGG CAG ATA-3’; and adiponectin: 5’-AAA GGA GAT CCA GTT CTT ATT GGT CCT AAG GGA-3’.

Immunohistochemistry
Immunohistochemistry for adiponectin and adiponectin receptors was performed in liver biopsies from a subgroup of study subjects (five patients with NAFLD and five with simple steatosis). Polyclonal antibodies against human adiponectin and human adiponectin receptors were purchased from R&D Systems (McKinley Place, Minnesota, USA) and Phoenix Pharmaceuticals (Belmont, California, USA), respectively. Sections (4 μm) were prepared from formalin fixed paraffin embedded tissue specimens, deparaffinised, and rehydrated in graded alcohols. A heat induced epitope retrieval technique by autoclaving slides for several minutes in 10 mM citric acid buffer was used for detection of adiponectin and its receptors. After quenching endogenous peroxidase with 3% H2O2 in phosphate buffered saline for 10 minutes, slides were incubated with primary antibodies at 4°C overnight (antihuman adiponectin pAb, 1 μg/ml; antihuman adiponectin receptor II pAb, 3 μg/ml). Specificity for adiponectin was demonstrated by blocking the primary antibody with recombinant human adiponectin (R&D Systems) at 4°C overnight. Solid phase absorbed rabbit Ig fraction (DakoCytomation, Glostrup, Denmark) was used to demonstrate specificity of adiponectin receptor II pAb staining. Visualisation was performed using the LSAB+ kit (DakoCytomation) with 3, 3’-diaminobenzidine as chromogen according to the manufacturer’s instructions. Sections

---

**Table 1** Anthropomorphic and clinical characteristics of all study patients

<table>
<thead>
<tr>
<th></th>
<th>NASH (n = 13)</th>
<th>Controls (n = 9)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>44 (3.1)</td>
<td>34 (4.3)</td>
<td>NS</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>9/4</td>
<td>7/2</td>
<td>NS</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>45.59 (3.8)</td>
<td>47.90 (2.69)</td>
<td>NS</td>
</tr>
<tr>
<td>AST (U/l)</td>
<td>26.75 (4.26)</td>
<td>21.44 (1.86)</td>
<td>NS</td>
</tr>
<tr>
<td>ALT (U/l)</td>
<td>41.17 (8.67)</td>
<td>23.44 (1.59)</td>
<td>NS</td>
</tr>
<tr>
<td>γ-GT (U/l)</td>
<td>49.83 (7.71)</td>
<td>27.62 (10.84)</td>
<td>NS</td>
</tr>
<tr>
<td>HOMA index</td>
<td>2.52 (0.61)</td>
<td>2.34 (0.87)</td>
<td>NS</td>
</tr>
<tr>
<td>Adiponectin (µg/ml)</td>
<td>5.38 (0.92)</td>
<td>6.86 (1.15)</td>
<td>NS</td>
</tr>
<tr>
<td>Grade of steatosis (1–4)</td>
<td>1.46 (0.24)</td>
<td>1.22 (0.22)</td>
<td>NS</td>
</tr>
<tr>
<td>Grade of fibrosis (1–4)</td>
<td>1.85 (0.25)</td>
<td>1.00 (0)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Grade of inflammation (1–4)</td>
<td>1.92 (0.21)</td>
<td>1.00 (0)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

NASH, non-alcoholic steatohepatitis; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, gamma glutamyl transferase; HOMA, homeostasis model assessment. Grade of steatosis, fibrosis, and inflammation were histologically verified and classified as: grade 1, no; grade 2, light; grade 3, mild; and grade 4, severe.

Values are means (SEM)
were counterstained with haematoxylin, dehydrated, and mounted permanently in Eukitt (O Kindler GmbH, Freiburg, Germany). Finally, sections were viewed on an Olympus IX70 with Kappa camera and Kappa ImageBase 2.2 software (Kappa opto-electronics GmbH, Gleichen, Germany). Staining intensity was semiquantitatively assessed in a blinded fashion by assigning an arbitrary value of 1, 2, or 3 (reflecting weak, intermediate, and bright staining) to each specimen.

Statistical analysis
Differences between groups were calculated using the Student’s t test for independent samples. Statistical significance was inferred at a two tailed p value of less than 0.05. Correlation coefficients were calculated using Pearson’s method. Descriptive data are expressed as mean (SEM). SPSS for windows (version 11.0) was used for statistical analysis.

RESULTS
Clinical characteristics
Clinical characteristics of study subjects are summarised in table 1. Body mass index, AST, ALT, γ-GT, and insulin sensitivity estimated by the HOMA index were similar in patients with NASH and simple steatosis. Serum adiponectin levels measured by radioimmunoassay were similar in patients with NASH (5.38 (0.92) mg/ml) and those with simple steatosis (6.86 (1.15) mg/ml; p = 0.18).

Hepatic mRNA expression
While the adipoRI/GAPDH cDNA ratio tended to be lower in liver biopsies of subjects with NASH without reaching statistical significance (4.91 (0.62) v 6.71 (2.03); p = 0.08), the adipoRII/GAPDH cDNA ratio was significantly decreased in liver biopsies of patients with NASH compared with those with simple steatosis (3.91 (0.35) v 7.96 (2.37); p = 0.04). The adiponectin/GAPDH cDNA ratio was significantly lower in liver biopsies of patients with NASH (0.15 (0.07)) compared with those with simple steatosis (0.66 (0.62); p = 0.01). AdipoRI/GAPDH, adipoRII/GAPDH, and adiponectin/GAPDH cDNA ratios are shown in fig 1.

Liver TNF-α cDNA/β-actin cDNA ratio, as determined by semiquantitative PCR analysis,11 was significantly higher in patients with NASH compared with those with simple steatosis (0.95 (0.16) v 0.22 (0.08); p<0.01) while liver TNF-α receptor type I (p55) and TNF-α receptor type II (p75) mRNA expression were similar in both groups.

Immunohistochemistry
Immunohistochemistry for adiponectin and adipoRII (fig 2) was performed in liver biopsies in a subgroup of our study patients (five with NASH and five with simple steatosis). Adiponectin protein expression was localised primarily to endothelial cells of portal vessels and liver sinusoids. Adiponectin staining was less pronounced in endothelial cells of liver sinusoids in patients with NASH (fig 2D, E) compared with subjects with simple steatosis (fig 2A–C) (1.4 (0.24) v 2.25 (0.25); p = 0.05). AdipoRII protein was localised to hepatocytes showing a predominantly cytoplasmic staining pattern. AdipoRII staining again tended to be less pronounced in liver biopsies of subjects with NASH (fig 2H) compared with subjects with simple steatosis (fig 2G) (1.6 (0.25) v 2.25 (0.25); p = 0.11).

Correlations of adiponectin and its receptors with other laboratory measurements
In subjects with NASH, adipoRII/GAPDH cDNA ratio was negatively correlated with AST (r = −0.68, p = 0.02), ALT
(r = -0.73, p = 0.01), and histological grade of fibrosis (r = -0.58, p = 0.04). Hepatic adiponectin mRNA expression was positively correlated with grade of steatosis in patients with simple steatosis (r = 0.969, p = 0.03) while no correlation was found between these parameters in subjects with NASH. Adiponectin/GAPDH cDNA expression was significantly correlated with serum levels of γ-GT (r = 0.86, p = 0.01) and alkaline phosphatase (r = 0.62, p = 0.04) in subjects with NASH. No correlations were observed with these laboratory parameters in patients with simple steatosis. No correlation was found between adiponectin and hepatic adiponectin, adiporiI, or adiportII mRNA expression in any group, respectively.

When subjects with NASH and simple steatosis were analysed together, hepatic adiponectin mRNA expression was correlated with liver TNF-α receptor type I (p55) mRNA expression (r = 0.51, p = 0.05) while no correlation between these parameters was found when subjects with NASH or simple steatosis were considered separately. Furthermore, no correlation was identified between mRNA expression of hepatic adiponectin or its receptors and liver TNF-α/TNF-α receptor type II (p75) mRNA expression in any group.

**DISCUSSION**

The aim of this study was to define a potential role of adipocyte-derived adiponectin and its receptors adiporiI and adiportII in the pathogenesis of NASH in patients with severe obesity. Our results suggest that in NASH, local effects of adiponectin are limited through two different mechanisms: (i) decreased adiponectin mRNA expression and (ii) decreased mRNA expression of hepatic adiporiI. Furthermore, we observed a negative correlation between adiporiI/GAPDH cDNA ratio and AST and ALT levels and grade of fibrosis. Our immunohistochemistry data further support the notion that adiponectin and adiporiI are diminished in NASH.

In contrast with adiporiI, hepatic adiportII mRNA expression was similar in NASH and simple steatosis. While adiporiI is predominantly expressed in the liver,

adiportII is mainly expressed in skeletal muscle,

suggesting that in the liver the effects of adiponectin are predominantly mediated by adiporiI. While adiporiI is a high affinity receptor for globular adiponectin, adiportII can mediate binding of both globular and full length adiponectin and thus can increase PPAR-α ligand activity and fatty acid oxidation by globular and full length adiponectin.10

Notably, adiponectin was mainly localised to endothelial cells of portal vessels and liver sinusoids while adiporiI was exclusively detected in hepatocytes. This may suggest that this hormone/receptor pair could function in a paracrine way in the liver and this interaction could be impaired in NASH. Furthermore, we found no correlation between circulating adiponectin levels and liver adiponectin expression. This could suggest that liver adiponectin expression is regulated by different factors, for example, proinflammatory cytokines such as TNF-α.

Recently, it was reported that TNF-α and adiponectin suppress each other’s production and are also able to antagonise each other’s action.4 Therefore, reduced adiponectin mRNA expression might be partially due to these suppressive effects of elevated TNF-α expression in NASH.11 13 In fact, we found increased liver TNF-α mRNA expression in subjects with NASH. Lack of a negative correlation between hepatic adiponectin mRNA expression and liver TNF-α mRNA expression might simply be due to the small number of subjects studied.

Decreased adiponectin liver activity may result in decreased fatty oxidation, glucose uptake, and reduced PPAR-α activity (which acts as the molecular target for lipid lowering fibrates and is strongly involved in hepatic fatty acid catabolism). Reduced effects of adiponectin on hepatic fatty acid metabolism could contribute to the development of steatohepatitis in patients with NASH. Our hypothesis is supported by the findings of Xu and colleagues who investigated the effects of adiponectin administration in ob/ob mice. The authors reported enhanced hepatic fatty acid oxidation and decreased acetyl-CoA carboxylase and fatty acid synthase activities—two key enzymes of fatty acid synthesis—after adiponectin delivery, resulting in reduced steatosis.

Recently, long term treatment with the PPAR-γ agonist rosiglitazone improved not only insulin sensitivity but also ALT levels and histological markers of NASH in overweight subjects with non-alcoholic fatty liver.15 In vitro, PPAR-γ plays a significant role in the transcriptional activation of the adiponectin gene. Therefore, the reported beneficial effect of rosiglitazone in patients with NASH may be due in part to the increasing effects of thiazolidinedione on adiponectin expression.19 20

In conclusion, we have demonstrated significantly decreased adiponectin and adiportII expression in liver biopsies of patients with NASH, suggesting that the functional pathway of this important adipokine and its liver specific receptor might be impaired in NASH.

**ACKNOWLEDGEMENTS**

This work was supported by grant P-15783-Med of the Austrian Science Fund (FWF) to HT and by a grant from the Spanish Ministerio de Educación y Ciencia, SAF.2001/0876 (FP).

**Authors’ affiliations**

S Kaser, C F Ebenbichler, J R Patch, University Hospital Innsbruck, Department of Medicine, Division of General Internal Medicine, Innsbruck, Austria

A Moschen, A Kaser, H Tilg, University Hospital Innsbruck, Department of Medicine, Division of Gastroenterology and Hepatology, Innsbruck, Austria

A Cayon, J Crespo, F Pons-Romero, University Hospital Marques de Valdecilla, School of Medicine, Institute of Digestive Diseases, Santander, Spain

Conflict of interest: None declared.

**REFERENCES**


www.gutjnl.com

Kaser, Moschen, Cayon, et al.


Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. Clinical Evidence needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

Areas for which we are currently seeking authors:

- Child health: nocturnal enuresis
- Eye disorders: bacterial conjunctivitis
- Male health: prostate cancer (metastatic)
- Women’s health: pre-menstrual syndrome; pyelonephritis in non-pregnant women

However, we are always looking for others, so do not let this list discourage you.

Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with Clinical Evidence editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every six months using any new, sound evidence that becomes available. The Clinical Evidence in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.
- To expand the topic to include a new question about once every 12–18 months.

If you would like to become a contributor for Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Klara Brunnhuber (kbrunnhuber@bmjgroup.com).

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Topics are usually 1500–3000 words in length and we would ask you to review between 2–5 topics per year. The peer review process takes place throughout the year, and our turnaround time for each review is ideally 10–14 days.

If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the peer review questionnaire at www.clinicalevidence.com or contact Klara Brunnhuber (kbrunnhuber@bmjgroup.com).
Adiponectin and its receptors in non-alcoholic steatohepatitis


Gut 2005 54: 117-121
doi: 10.1136/gut.2003.037010